Grifols S.A. ADR Stock
Grifols S.A. ADR Stock
A loss of -1.320% shows a downward development for Grifols S.A. ADR.
Pros and Cons of Grifols S.A. ADR in the next few years
Pros
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
B****
Cons
?
M***** P*******
?
S********** s********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Grifols S.A. ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Grifols S.A. ADR | -1.320% | -8.982% | -0.654% | 8.571% | 0.000% | -11.628% | -39.816% |
| Eledon Pharmaceuticals Inc. | 0.000% | 16.763% | 15.429% | -47.668% | 57.813% | -15.833% | -84.812% |
| Beximco Pharmaceuticals Ltd. GDR | -6.360% | 6.796% | 3.774% | 26.728% | 22.768% | 10.887% | -43.005% |
| SELLAS Life Sciences Group Inc | -1.560% | 21.076% | 14.897% | 277.949% | 46.914% | 154.662% | -38.424% |
Comments
Grifols, S.A. (NASDAQ: GRFS) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating.
Show more
Ratings data for GRFS provided by MarketBeat
Grifols, S.A. (NASDAQ: GRFS) was downgraded by analysts at Wall Street Zen from a "strong-buy" rating to a "buy" rating.
Show more
Ratings data for GRFS provided by MarketBeat
Grifols, S.A. (NASDAQ: GRFS) is now covered by analysts at Morgan Stanley. They set an "overweight" rating on the stock.
Show more
Ratings data for GRFS provided by MarketBeat